Veterinary Medicines

BOVIBIO KOLIVAC RC, ενέσιμο γαλάκτωμα για βοοειδή

Authorised
  • Bovine rotavirus A, type G6P1, strain TM-91, Inactivated
  • Bovine coronavirus, strain C-197, Inactivated
  • Escherichia coli, serotype O8:K35 (fimbrial adhesin F5), Inactivated
  • Escherichia coli, serotype O9:K35 (fimbrial adhesin F5), Inactivated
  • Escherichia coli, serotype O101:K30 (fimbrial adhesin F5), Inactivated
Download as PDF

Product identification

Medicine name:
BOVIBIO KOLIVAC RC, ενέσιμο γαλάκτωμα για βοοειδή
Active substance:
  • Bovine rotavirus A, type G6P1, strain TM-91, Inactivated
  • Bovine coronavirus, strain C-197, Inactivated
  • Escherichia coli, serotype O8:K35 (fimbrial adhesin F5), Inactivated
  • Escherichia coli, serotype O9:K35 (fimbrial adhesin F5), Inactivated
  • Escherichia coli, serotype O101:K30 (fimbrial adhesin F5), Inactivated
Target species:
  • Cattle (pregnant cow)
  • Cattle (heifer)
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Bovine rotavirus A, type G6P1, strain TM-91, Inactivated
    1.00
    relative potency
    /
    2.00
    millilitre(s)
  • Bovine coronavirus, strain C-197, Inactivated
    1.00
    relative potency
    /
    2.00
    millilitre(s)
  • Escherichia coli, serotype O8:K35 (fimbrial adhesin F5), Inactivated
    1.00
    relative potency
    /
    2.00
    millilitre(s)
  • Escherichia coli, serotype O9:K35 (fimbrial adhesin F5), Inactivated
    1.00
    relative potency
    /
    2.00
    millilitre(s)
  • Escherichia coli, serotype O101:K30 (fimbrial adhesin F5), Inactivated
    1.00
    relative potency
    /
    2.00
    millilitre(s)
Pharmaceutical form:
  • Emulsion for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle (pregnant cow)
      • Meat and offal
        0
        day
    • Cattle (heifer)
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AL01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Greece
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Complete application (stand-alone)
Marketing authorisation holder:
  • Neocell Ltd.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta, a.s.
Responsible authority:
  • National Organization For Medicines
Authorisation number:
  • 54850/13-05-2025/K-0228701
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Greek (PDF)
Published on: 27/03/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Greek (PDF)
Published on: 27/03/2024
Download